Bahasa

   Home      Contact

 

FAQ
Contact


RHEUMATICS


1. What is rheumatism?


Rheumatism is a collection of symptoms affecting limbs, especially bones, joints, muscles and spine, along with pain and dysfunction. These could be accompanied by swelling or other signs of inflammation and dysfunction.

2. Is rheumatism only a disease of the elderly?

No, rheumatism could affect all ages, from newborn to the elderly, only with different cause and frequency. It mostly affects the 40-50 year-old and above, caused by calcification and bone loss. Sometimes it is caused by inflammation and increased uric acid level.


3. What are the symptoms?

Pain, swelling, dysfunction of the limbs or other more severe impairment of movements may occur with rheumatism.


4.
What is the treatment?


It depends on the cause. For example, inflammation is treated with anti-inflammatory drugs and pain-killer. If inflammation is due to autoimmune process, immuno-suppressants are given. If there is calcification, medicine to prevent calcification is given, along with weight-bearing reduction and posture correction, and also weight-loss. Treatments to reduce calcification also include joint and muscle training, physiotherapy and administration of joint lubricant. If there is bone-loss, medication preventing further bone-loss should be given together with calcium supplement. Medication to increase bone-mass could also be administered.

5. Is there a new therapy or treatment method for
    rheumatic disease?


It depends on the disease, especially for inflammatory arthritis like Rheumatoid Arthritis (RA), Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis (JRA) there is a new therapy which provides good result but relatively expensive. It is given by injection twice weekly and given for several months until the disease is controlled. The drug is Anti DNF-a (Enbrel) and some other medications.

6. What is the condition of rheumatic patients in Indonesia?

In adults the process is as follows: mechanical muscle pain, calcification and inflammation (due to autoimmune process or accumulation of uric acid, and sometimes due to bacterial infection), to bone-loss and resulting to bone fracture, especially in the elderly. While in children, it is usually caused by hereditary abnormalities or joint inflammation.

7. How could it be prevented early?

Prevention should be tailored to its cause. For example mechanical pain should be prevented by correct posture and correct working methods or body weight-bearing. If it is autoimmune, prevention would be difficult except for early treatment to prevent disease progression. Calcification, which is common after middle age, could be prevented by reducing excessive joint loading and weight reduction. Bone loss should be prevented early by ensuring adequate calcium intake and if necessary bone mass measurement so that the right treatment could be provided. Prevention could be done by taking calcium (in milk), physical exercise and if necessary taking hormone replacement or drugs to improve bone strength like biphosphonate.


 

OSTEOPOROSIS
 

1. What is osteoporosis?


Osteoporosis is a disease affecting the bones which is characterised by a decrease in bone mass and density that increases the risk of broken bones, particularly in the spine, wrist, hip, pelvis and upper arm. The disease occurs in women after the menopause.

Unfortunately most people don't know they have osteoporosis until they break a bone. As such, a new WHO study has stated that early detection of low bone density could significantly reduce the impact of osteoporosis.

Osteoporosis can be diagnosed relatively easily by:
• medical history
• basic investigations, including x-rays
• bone mass density
– QCT (quantitative computed tomography)
– QUS (quantitative ultrasound scanning)
• DXA (DEXA) dual energy x-ray absorptiometry
• biochemical markers of bone turnover (serum + urine)
– bone formation
– bone breakdown

2. Is Osteoporosis a new disease?

No, osteoporosis is as old as human civilization. Hippocrates described thinning and tendency to fracture of the bones in the aged. Only the last 50 years, medical science has begun to shed some lights on the nature of the disease.


3. Why is everybody so concerned about Osteoporosis
    nowadays?

The electronic media in particular the daily TV advertisements in promoting the sales of milk and milk products daily induce awareness of osteoporosis in the community. This is a good thing, but on the other hand it creates misinformation what milk and milk products can do against osteoporosis.


4.
Can food supplements prevent or be used for treatment
    of Osteoporosis?


No, milk, milk products, and calcium in tablets, liquid, and powder are food components that everybody must take daily to grow and remain healthy until old age. These are not medicines to cure or prevent osteoporosis. To treat and prevent osteoporosis we require adequate nutrition and this includes milk and milk products.

 

  Email This Page   Print This Page

 
NEWS & EVENTS

LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

16.11.2005
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis


Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart

more

 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.09.2005
Roche files first rheumatoid arthritis indication for MabThera in Europe

MabThera: a medicine used to treat non-Hodgkin's lymphoma


MabThera delivers significant and sustained relief from symptoms in patients with difficult-to-treat rheumatoid arthritis.
more

 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.04.2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies

Third large randomised trial to evaluate efficacy and safety of MabThera in RA

Roche, Genentech and Biogen Idec announced today that REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its primary endpoint in the group of patients with the most difficult-to-treat rheumatoid arthritis (RA).

more

Legal Disclamer

Legal Disclaimer

Copyright ©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases.

This Web site was developed in 2005 as a service provided by the WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases. This Web site provides selected information available about lupus and arthritis. It is important that public see a healthcare professional for detailed information about medical conditions and treatment. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. The WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases has made and will continue to make efforts to include accurate and up-to-date information on this Web site.

If you have any questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
 


Supported by PT Roche Indonesia